What sponsors should know about FDA’s platform technology designation

Platform designation is a regulatory program introduced by the FDA to streamline the development and approval process for advanced therapies. In May 2024, the FDA issued draft guidance outlining eligibility and benefits of this designation for biologics, including adeno-associated virus (AAV)-based gene therapies.¹

The guidance enables sponsors with a licensed gene therapy to reference established manufacturing, analytical and safety data for subsequent candidates using the same vector platform. To qualify, the platform must already be incorporated in an approved product, and the new therapy must demonstrate shared characteristics with the original product.

This pathway holds particular relevance for AAV-based programs. With proper alignment, it allows developers to leverage platform data to accelerate development timelines and reduce regulatory burden. While the full designation applies post-approval, the FDA clarifies that sponsors can still use prior submissions to support new applications if scientifically justified. This flexibility has important implications for development efficiency, especially for companies operating under tight timelines or in rare disease settings where rapid delivery is critical.

Key elements of the guidance

According to the draft guidance, platform designation may be granted when:

• The platform is incorporated in an approved product;
• Preliminary evidence suggests it can support more than one product without negatively affecting quality or safety and;
• Use of the platform offers efficiency in manufacturing and regulatory review.

Acceptable evidence may include similarities in nucleic acid sequence, vector capsid, targeting moieties, or formulation. Minimal differences in manufacturing processes and consistency in purification strategies are also important.

The FDA encourages early communication between sponsors and the agency to discuss potential eligibility. A strong data package, built from prior submissions or related INDs/BLAs, helps demonstrate continuity of the platform’s performance across candidates.²

Importantly, the guidance distinguishes platform designation from the broader concept of more generalized platform approaches. Sponsors may still leverage their prior data across programs even without formal designation. This is particularly relevant when the designation pathway may not apply due to timing or scope, but where the use of prior knowledge still brings development advantages. In comments at the Alliance for Regenerative Medicine’s Cell & Gene State of the Industry Briefing in January 2025, Dr. Peter Marks addressed the concept of leveraging nonclinical and manufacturing data to inform “offshoot” products in a platform context.³

A platform approach to AAV development

An effective platform strategy involves aligning key manufacturing, analytical and quality systems to minimize variability across programs.

End-to-end capabilities, including plasmid production and final drug product, are important. Harmonization of equipment between development and manufacturing, templated documentation, and standardized consumables facilitate consistent technology transfer and minimizes process deviation risk. 

Contract development and manufacturing organizations (CDMOs) can play an important role in enabling sponsors to realize the benefits of platform designation. Look for CDMOs that operate global networks of FDA- and EMA-inspected facilities that offer end-to-end services for viral vector production. These capabilities may include plasmid raw material production, process development and scale-up, clinical and commercial manufacturing, fill/finish services, and analytical testing across multiple sites.

To support consistency throughout development and manufacturing, CDMOs often use unified systems and equipment. A design of experiment (DOE) approach applied early in development can help define the process design space and optimize operating conditions, with the goal of maximizing vector yield and quality and supporting the overall success of the therapeutic product.

Use of off-the-shelf materials

Program sponsors and CDMOs can accelerate timelines by utilizing ready-to-use, pre-qualified materials. For example:

• Standard helper plasmids and RepCap vectors for multiple AAV serotypes;
• A clonal cell line with superior performance attributes for quality and productivity and;
• Pre-qualified analytical methods for characterization and release.

These components reduce the need for custom development and further support a platform-based approach. When these materials are available in both R&D and GMP grades, they enable seamless transition from early development to clinical production. 

Process development and analytical alignment

Small-scale experimentation supports rapid process optimization. DOE studies evaluating plasmid ratios, transfection reagents, and cell densities define locked processes that perform consistently on scale-up. These data feed directly into downstream development, risk assessment and process-lock ahead of transfer to manufacturing.

Equally important are integrated in-process analytics and platform-ready assays, including droplet digital polymerase chain reaction (ddPCR) for genome titer, sedimentation velocity analytical ultracentrifugation (SV-AUC) for capsid packaging, capillary electrophoresis–sodium dodecyl sulfate (CE-SDS) for purity, tissue culture infectious dose 50% (TCID50) for infectivity, and a suite of residual impurity assays, essential for early comparability assessment and regulatory filing.

To enhance platform understanding, program sponsors and CDMOs should share and closely review development data for the sponsor’s set of ‘platform molecules,’ including assay performance, titer trends and impurity profiles. This transparency supports alignment on critical quality attributes (CQAs) and critical process parameters (CPPs) ahead of progression to late-stage clinical production and process validation.

Analytical method strategy

An effective analytical method strategy for AAV gene therapies requires a tiered and modular approach. Developers typically organize methods into categories such as strength (e.g., genome and infectious titers), identity and purity (e.g., CE-SDS, ELISA, mass spectrometry), safety (e.g., sterility, endotoxin), and process-related impurities (e.g., host cell protein, plasmid, residual DNA). By prequalifying and standardizing these assays where possible, sponsors will reduce assay development timelines, ensure cross-program consistency, and streamline regulatory filings.

Platform analytics often include a mix of client-specific methods, prequalified methods requiring suitability, characterization assays, and compendial methods requiring verification. This modular setup supports scalability from early development through GMP release and commercialization, while accommodating product-specific assays such as potency tests.

Early coordination across analytical development, regulatory strategy, and clinical timelines is essential to ensure assays are aligned with phase-appropriate quality expectations. This framework supports platform designation readiness and enables the application of analytical data across related gene therapy programs.

Compliant process validation 

A structured validation life cycle, from process characterization to continued verification, aligns with FDA, EMA, and ICH expectations. Early engagement with regulatory guidelines helps ensure that development milestones support eventual process performance qualification (PPQ) and commercial readiness.

Key steps include:

• Scale-down model development;
• Identification of critical process parameters and quality attributes;
• Risk-based validation protocol development and;
• Execution of PPQ runs.

A well-documented validation master plan should outline strategy and description around facilities and equipment qualification, process validation, and should reference related protocols, procedures, and persons responsible for approvals. The site master plan can provide additional detail around computerized system validation, for example. CDMOs should support sponsors by providing validation templates and historical perspective on ranges for key inputs.

Control strategy development incorporates in-process monitoring, hold time and process limits, predefined specifications, and life cycle risk management to ensure commercial readiness. Continuous process verification (CPV) programs are typically launched post-approval but require a foundation of data from development and validation stages.

Late-stage development and commercialization

A platform-ready approach enables smoother transition into late-phase trials and commercial production. Standardized systems and documented performance history support predictable process performance and product consistency at scale.

Late-stage activities include:

• Scaling up cell culture and vector purification processes;
• Confirming robustness of fill/finish steps and;
• Executing registration batches for regulatory submissions.

CDMOs with flexible capacity and modular suites can accommodate varying batch sizes while maintaining consistency. Documentation packages must also evolve to meet regulatory expectations for commercial supply, including product specifications and stability data.

Implications for sponsors

Instead of treating each gene therapy as a standalone effort, the FDA has signaled support for repeatable systems that can be adapted for multiple products. When a vector platform is well-characterized and incorporated into an approved product, future applications using the same backbone may qualify for streamlined development and regulatory review.

For sponsors, this approach reduces single-asset risk and supports the use of common manufacturing processes across a portfolio. It also underscores the value of working with manufacturing partners that have platform-based infrastructure and experience supporting licensed therapies.

This evolving regulatory mindset enables sponsors to build broader pipelines around core vector technologies. With appropriate data and operational readiness, companies can benefit from faster timelines and greater predictability, especially in indications with high unmet medical need.⁴

As gene therapy evolves, platform designation provides an effective way to minimize redundancy and speed up development. Successful application requires more than scientific justification; it also depends on operational readiness, analytical rigor and validated processes. 

References

1. U.S. FDA. (2024, May). Platform Technology Designation Program for Drug Development. [Guidance Document]
2. Benton, K. (2024, June). What Does FDA’s Draft Platform Guidance Mean For CGT Companies? Cell & Gene.
3. Marks, P. (2025, Jan 13). Updates on the FDA’s Efforts to Accelerate Advances in Cell and Gene Therapy. ARM Cell & Gene State of the Industry Briefing. [Industry presentation]
4. Berry, D. et. al. (2024 Dec). Optimizing regulatory frameworks for gene therapies in rare diseases: Challenges and solutions. Mol Ther Methods Clin Dev. 32(4):101386.